Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Protocol No

HJKC3-0003

Phase

II

Summary

The purpose of this study is to determine if adding asciminib to imatinib prior to a second attempt at stopping imatinib will lead to prolonged treatment free remission.

Description

Treatment Free Remission After Asciminib plus Imatinib in CP-CML

Participating Institutions

Karmanos Cancer Institute

Memorial Sloan Kettering Cancer Center

University of Utah Huntsman Cancer Institute

Froedtert Hospital

Moorland Reserve Health Center

Memorial Sloan Kettering Cancer Center - Bergen

Lawrence And Idell Weisberg Cancer Treatment Center

Memorial Sloan Kettering Cancer Center - Monmouth

Status

OPEN TO ACCRUAL